Delivery Order SPE2DB24D1201-SPE2DB25FJEFS
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors valued at $9,253.56 on July 30, 2025, with a completion date of July 31, 2025. This firm fixed price, non-competitive delivery order represents pharmaceutical procurement for military healthcare needs and is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $36,351.37 to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of ENBREL 50 mg/ml SureClick auto-injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 17, 2025, and represents a non-set-aside competitive award. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a $70,640.79 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors, with performance in Conshohocken, Pennsylvania and completion targeted for August 26, 2025. This competitively awarded, firm fixed-price contract is a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,543.12 to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml SureClick auto-injectors, with an ultimate completion date of September 19, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office in...
- The Defense Logistics Agency (DLA) awarded a $35,072.01 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL SureClick auto-injectors, with an ultimate completion date of August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place of performance is listed...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,177.44 to AmerisourceBergen Drug Corp for ENBREL 50 mg/mL SureClick auto-injectors, with an ultimate completion date of June 20, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $25,207.11 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml SureClick auto-injectors, with an ultimate completion date of June 26, 2025. This non-set-aside, competitively awarded contract employs firm fixed price terms and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $31,964.22 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/mL SureClick auto-injectors, with an ultimate completion date of September 5, 2025. This non-competitive delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement valued through December 2026. The product being delivered—ENBREL, a...
- The Defense Logistics Agency (DLA) awarded a $5,423.23 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL SureClick auto-injectors, with completion targeted for November 3, 2025. This non-set-aside award was issued on October 31, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $62,786.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of ENBREL 50 mg/ml SureClick auto-injectors. This competitively awarded, non-set-aside contract is scheduled for ultimate completion by September 15, 2025, with fulfillment performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJEFSDelivery Order
The Defense Logistics Agency (DLA) awarded a $30,416.77 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml SureClick auto-injectors, with an ultimate completion date of September 18, 2025. This is a firm fixed-price, non-set-aside contract issued to the prime contractor's corporate office located in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00 prime vendor agreement valued through December 2026 that authorizes the company to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare operations. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal medical procurement vendor, particularly for the Defense Health Agency and military healthcare systems. The company's federal contract portfolio demonstrates extensive experience fulfilling competitively awarded delivery orders for specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This specific delivery order for ENBREL, a prescription immunosuppressant used primarily for rheumatoid arthritis treatment, reflects the company's established capability to supply specialty pharmaceutical products to support federal medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $30.4k | 9/17/25 |